JP2018503603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503603A5 JP2018503603A5 JP2017528894A JP2017528894A JP2018503603A5 JP 2018503603 A5 JP2018503603 A5 JP 2018503603A5 JP 2017528894 A JP2017528894 A JP 2017528894A JP 2017528894 A JP2017528894 A JP 2017528894A JP 2018503603 A5 JP2018503603 A5 JP 2018503603A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- antibody
- complex compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 230000003115 biocidal effect Effects 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 229930189077 Rifamycin Natural products 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003292 rifamycin Drugs 0.000 claims 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical compound BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- -1 glidant Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SGHWBDUXKUSFOP-KYALZUAASA-N rifalazil Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N=C2C(=O)C=3C(O)=C4C)C)OC)C4=C1C=3C(NC1=C(O)C=3)=C2OC1=CC=3N1CCN(CC(C)C)CC1 SGHWBDUXKUSFOP-KYALZUAASA-N 0.000 claims 1
- 229950005007 rifalazil Drugs 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087184P | 2014-12-03 | 2014-12-03 | |
| US62/087,184 | 2014-12-03 | ||
| PCT/US2015/063510 WO2016090038A1 (en) | 2014-12-03 | 2015-12-02 | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503603A JP2018503603A (ja) | 2018-02-08 |
| JP2018503603A5 true JP2018503603A5 (cg-RX-API-DMAC7.html) | 2019-01-17 |
| JP6742314B2 JP6742314B2 (ja) | 2020-08-19 |
Family
ID=55070136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528894A Expired - Fee Related JP6742314B2 (ja) | 2014-12-03 | 2015-12-02 | 抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180021450A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3226911A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6742314B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170086536A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107206102A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017011325A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2965540A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1243931A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017007055A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2731055C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016090038A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3082875B1 (en) | 2013-12-16 | 2020-11-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| HK1222577A1 (zh) | 2013-12-16 | 2017-07-07 | Genentech Inc. | 擬肽化合物及其抗體藥物偶聯物 |
| WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017152083A1 (en) * | 2016-03-04 | 2017-09-08 | Genentech, Inc. | Process for the preparation of an antibody-rifamycin conjugate |
| KR20190074310A (ko) | 2016-11-08 | 2019-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| JP7364471B2 (ja) | 2017-05-18 | 2023-10-18 | レゲネロン ファーマシューティカルス，インコーポレーテッド | シクロデキストリンタンパク質薬物コンジュゲート |
| CA3080857A1 (en) | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| MA50259A1 (fr) | 2018-01-08 | 2021-07-29 | Regeneron Pharma | Stéroïdes et leurs conjugués-anticorps |
| EP3743060A4 (en) | 2018-01-24 | 2021-11-03 | The Rockefeller University | ANTIBACTERIAL COMPOUNDS, RELATED COMPOSITIONS AND THEIR METHODS OF USE |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| US11666658B2 (en) | 2018-12-21 | 2023-06-06 | Regeneran Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
| CN110174363A (zh) * | 2019-01-09 | 2019-08-27 | 北京九强生物技术股份有限公司 | 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途 |
| WO2021016433A1 (en) | 2019-07-23 | 2021-01-28 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
| WO2021242849A1 (en) * | 2020-05-28 | 2021-12-02 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
| JP7613580B2 (ja) | 2021-06-01 | 2025-01-15 | 味の素株式会社 | 抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる化合物またはその塩 |
| CN117659042B (zh) * | 2023-12-05 | 2024-12-27 | 北京大学第三医院（北京大学第三临床医学院） | 利福霉素衍生物及其制备方法和用途 |
| CN118598380B (zh) * | 2024-08-08 | 2024-10-22 | 生态环境部南京环境科学研究所 | 一种长效修复石油化工企业地下水石油烃污染的方法 |
| CN119701000A (zh) * | 2024-12-25 | 2025-03-28 | 中国人民解放军空军军医大学 | 一类多肽偶联药物及其制备方法和应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB877732A (en) | 1958-08-12 | 1961-09-20 | Lepetit Spa | The antibiotic rifomycin, its components and methods of preparing same |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4610919A (en) | 1985-06-14 | 1986-09-09 | Fiber Bond Corporation | Binder for fibrous padding |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| JP2544375B2 (ja) | 1986-07-14 | 1996-10-16 | 鐘淵化学工業株式会社 | アルキル置換ベンゾキサジノリフアマイシン誘導体 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA1304363C (en) | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| US6660267B1 (en) | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| US5545721A (en) | 1992-12-21 | 1996-08-13 | Ophidian Pharmaceuticals, Inc. | Conjugates for the prevention and treatment of sepsis |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5981522A (en) | 1995-09-01 | 1999-11-09 | Kaneka Corporation | Treatment of disease caused by infection of Helicobacter |
| JP3963976B2 (ja) | 1995-12-08 | 2007-08-22 | 株式会社カネカ | クラミジア感染症治療剤 |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US7101692B2 (en) * | 1999-04-15 | 2006-09-05 | The Regents Of The University Of California | Identification of sortase gene |
| CA2373221A1 (en) | 1999-05-03 | 2000-11-30 | Yashwant M. Deo | Human antibodies to staphylococcus aureus |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7017718B2 (en) * | 2001-06-28 | 2006-03-28 | Freni Brembo S.P.A | Composite disc for a disc brake having a splittable braking band |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| EP1482972A4 (en) | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
| EP1453837A4 (en) * | 2001-11-21 | 2007-11-07 | Activbiotics Inc | TARGETED THERAPEUTIC AGENTS AND USES THEREOF |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| WO2004032828A2 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| WO2004050846A2 (en) * | 2002-12-02 | 2004-06-17 | Biosynexus Incorporated | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| KR20070029616A (ko) | 2003-08-22 | 2007-03-14 | 액티브 바이오틱스 인코포레이티드 | 리파마이신 유사체 및 그의 용도 |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| KR101520209B1 (ko) * | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005062882A2 (en) | 2003-12-23 | 2005-07-14 | Activbiotics, Inc | Rifamycin analogs and uses thereof |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| KR101327635B1 (ko) * | 2005-08-11 | 2013-11-12 | 타간타 테라퓨틱스 인크. | 포스폰산화 리파마이신, 및 그의 뼈 및 관절 감염의 저지및 치료 용도 |
| AU2006326456A1 (en) | 2005-12-14 | 2007-06-21 | Activbiotics Pharma Llc | Rifamycin analogs and uses thereof |
| ES2654847T3 (es) * | 2006-04-19 | 2018-02-15 | Novartis Ag | Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R |
| EP2024394B1 (en) * | 2006-06-06 | 2014-11-05 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof |
| HRP20110686T1 (hr) | 2007-03-01 | 2011-10-31 | Symphogen A/S | Postupak kloniranja srodnih protutijela |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| CA2760493A1 (en) | 2008-05-12 | 2009-11-19 | Strox Biopharmaceuticals, Llc | Staphylococcus aureus-specific antibody preparations |
| US8524691B2 (en) | 2008-08-13 | 2013-09-03 | The Medicines Company | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| AU2009302582A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins |
| SG177653A1 (en) * | 2009-07-15 | 2012-02-28 | Aimm Therapeutics Bv | Gram-positive bacteria specific binding compounds |
| CN119552249A (zh) | 2010-06-08 | 2025-03-04 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| AU2012395148B2 (en) * | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| BR112015029754A2 (pt) * | 2013-05-31 | 2017-09-26 | Genentech Inc | anticorpos anti-teicoico da parede e conjugados |
| US9803002B2 (en) * | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| EP3381939A1 (en) | 2013-05-31 | 2018-10-03 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| AR096388A1 (es) * | 2013-05-31 | 2015-12-30 | Genentech Inc | Anticuerpos anti-ácido teicoico de pared y sus conjugados |
-
2015
- 2015-12-02 BR BR112017011325-2A patent/BR112017011325A2/pt not_active Application Discontinuation
- 2015-12-02 CN CN201580075298.5A patent/CN107206102A/zh active Pending
- 2015-12-02 KR KR1020177014576A patent/KR20170086536A/ko not_active Withdrawn
- 2015-12-02 JP JP2017528894A patent/JP6742314B2/ja not_active Expired - Fee Related
- 2015-12-02 RU RU2017118793A patent/RU2731055C2/ru active
- 2015-12-02 CA CA2965540A patent/CA2965540A1/en not_active Abandoned
- 2015-12-02 WO PCT/US2015/063510 patent/WO2016090038A1/en not_active Ceased
- 2015-12-02 EP EP15820347.1A patent/EP3226911A1/en not_active Withdrawn
- 2015-12-02 MX MX2017007055A patent/MX2017007055A/es unknown
- 2015-12-02 HK HK18103430.2A patent/HK1243931A1/zh unknown
-
2017
- 2017-06-02 US US15/611,985 patent/US20180021450A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503603A5 (cg-RX-API-DMAC7.html) | ||
| JP2018507166A5 (cg-RX-API-DMAC7.html) | ||
| RU2017118793A (ru) | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение | |
| RU2017118792A (ru) | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение | |
| JP2016525343A5 (cg-RX-API-DMAC7.html) | ||
| RU2015151046A (ru) | Антитела против стеночной тейхоевой кислоты и их конъюгаты | |
| ES2757675T3 (es) | Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile | |
| TW202334217A (zh) | 抗體的特異性偶聯 | |
| Singh | β-Lactams in the new millennium. Part-II: cephems, oxacephems, penams and sulbactam | |
| JP2018516243A5 (cg-RX-API-DMAC7.html) | ||
| JP2015528818A5 (cg-RX-API-DMAC7.html) | ||
| JP2015527318A5 (cg-RX-API-DMAC7.html) | ||
| JP2016502504A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537893A5 (cg-RX-API-DMAC7.html) | ||
| JP2018511628A5 (cg-RX-API-DMAC7.html) | ||
| EP3086814A1 (de) | Binder-konjugate (adcs) mit ksp-inhibitoren | |
| JP2015534580A5 (cg-RX-API-DMAC7.html) | ||
| FI3316909T3 (fi) | NTB-A-vasta-aineita ja liittyviä koostumuksia ja menetelmiä | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2011500725A5 (cg-RX-API-DMAC7.html) | ||
| JP2015534578A5 (cg-RX-API-DMAC7.html) | ||
| JP2015534579A5 (cg-RX-API-DMAC7.html) | ||
| JP2016520082A5 (cg-RX-API-DMAC7.html) | ||
| EP3313522A1 (de) | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern | |
| CN110279872A (zh) | 细胞毒素分子同细胞结合受体分子的共轭体 |